Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations.

Alexander JJ, Colangelo PM, Cooper CK, Roberts R, Rodriguez WJ, Murphy MD.

Pediatr Infect Dis J. 2008 Nov;27(11):955-7. doi: 10.1097/INF.0b013e31817bf9a9.

PMID:
18833025
2.

Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.

Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.

Antimicrob Agents Chemother. 2010 May;54(5):1678-83. doi: 10.1128/AAC.00737-08.

3.

No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.

Baggett HC, Rhodes JC, Fridkin SK, Quinn CP, Hageman JC, Friedman CR, Dykewicz CA, Semenova VA, Romero-Steiner S, Elie CM, Jernigan JA.

Clin Infect Dis. 2005 Oct 1;41(7):991-7.

PMID:
16142664
4.

Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2013 Dec;57(12):5946-60. doi: 10.1128/AAC.02616-12.

5.

Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.

Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF.

Antimicrob Agents Chemother. 2006 Nov;50(11):3535-42.

6.

US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.

Meyerhoff A, Albrecht R, Meyer JM, Dionne P, Higgins K, Murphy D.

Clin Infect Dis. 2004 Aug 1;39(3):303-8. Review.

PMID:
15306995
7.

Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.

Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly M, Drusano GL.

Antimicrob Agents Chemother. 2005 Dec;49(12):5099-106.

8.

An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.

Martin SW, Tierney BC, Aranas A, Rosenstein NE, Franzke LH, Apicella L, Marano N, McNeil MM.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):393-401.

PMID:
15717323
9.

Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2001 Nov 16;50(45):1014-6.

10.

Antimicrobial susceptibility of Bacillus anthracis in an endemic area.

Bakici MZ, Elaldi N, Bakir M, Dökmetaş I, Erandaç M, Turan M.

Scand J Infect Dis. 2002;34(8):564-6.

PMID:
12238569
11.

Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.

Li F, Nandy P, Chien S, Noel GJ, Tornoe CW.

Antimicrob Agents Chemother. 2010 Jan;54(1):375-9. doi: 10.1128/AAC.00667-09.

12.

Bacillus anthracis and antibacterial agents.

Bryskier A.

Clin Microbiol Infect. 2002 Aug;8(8):467-78. Review.

13.

Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001.

Jefferds MD, Laserson K, Fry AM, Roy S, Hayslett J, Grummer-Strawn L, Kettel-Khan L, Schuchat A; Centers for Disease Control and Prevention Anthrax Adherence Team..

Emerg Infect Dis. 2002 Oct;8(10):1138-44.

14.

Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.

Kihira T, Sato J, Shibata T.

J Infect Chemother. 2004 Apr;10(2):97-100.

PMID:
15160302
15.

Pediatric anthrax: implications for bioterrorism preparedness.

Bravata DM, Wang E, Holty JE, Lewis R, Wise PH, Nayak S, Liu H, McDonald KM, Owens DK.

Evid Rep Technol Assess (Full Rep). 2006 Aug;(141):1-48. Review.

16.

Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign.

Shaffer D, Armstrong G, Higgins K, Honig P, Coyne P, Boxwell D, Beitz J, Leissa B, Murphy D.

Pharmacoepidemiol Drug Saf. 2003 Apr-May;12(3):177-82.

PMID:
12733470
17.

Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3973-9. doi: 10.1128/AAC.00453-08.

18.

The prophylaxis and treatment of anthrax.

Brook I.

Int J Antimicrob Agents. 2002 Nov;20(5):320-5. Review.

PMID:
12431866
19.

Pediatric anthrax clinical management.

Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, Meaney-Delman D, Pavia AT; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council..

Pediatrics. 2014 May;133(5):e1411-36. doi: 10.1542/peds.2014-0563.

20.

Cutaneous anthrax in Turkey: a review of 32 cases.

Oncül O, Ozsoy MF, Gul HC, Koçak N, Cavuslu S, Pahsa A.

Scand J Infect Dis. 2002;34(6):413-6. Review.

PMID:
12160166
Items per page

Supplemental Content

Support Center